Ichor, Profectus announce agreement for clinical development of DNA vaccine programs

April 21, 2016

Dr. John Eldridge, Profectus Chief Scientific Officer, stated, ???We are excited to be entering into the clinic using Ichor??s TriGrid?? delivery system for the delivery of our DNA vaccines both alone, and in prime/boost combination with our rVSV vaccine vector. Profectus has made significant clinical progress in advancing our vaccine programs using this multi-pronged approach. We believe that by combining our proprietary DNA vaccine technology with novel molecular adjuvants, improved formulation and a powerful delivery system, Profectus will overcome the previous challenges of efficiently delivering DNA vaccines in vivo.???

???We are delighted to be working with the experienced team at Profectus and believe this Agreement further validates the utility of our TriGrid?? technologies for a variety of DNA vaccine approaches. We are pleased to provide our enabling TriGrid?? technology to Profectus for clinical delivery of its ProfectusVAX?? portfolio of DNA vaccines,??? said Bob Bernard, Ichor CEO.

The first clinical vaccine candidate for HIV is planned for clinical trials in Q2??10, followed by a therapeutic HCV vaccine. Financial details of the agreement were not disclosed.

SOURCE Ichor Medical Systems